ARQT · NASDAQ
Arcutis Biotherapeutics, Inc.
$28.97 -3.04 (-9.50%)
Company overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical Janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $3.6B
- Employees
- 342
- Headquarters
- Westlake Village, CA
- Website
- arcutis.com
- CEO
- Todd Franklin Watanabe
- Listed
- January 31, 2020
- P/E
- -1,508.85
- Dividend yield
- 0.00%
Company financials
- Revenue
- $416M
- Gross profit
- $378M
- Operating income
- $3.2M
- EBITDA
- $12.8M
- Net income
- -$2.4M
- EPS
- -$0.02
- Total assets
- $460M
- Total debt
- $13.2M
- Gross margin
- 90.94%
- Net margin
- -0.57%
- Earnings yield
- -0.07%
No geographic segmentation.
Showing FY 2023
ARQT
1D
NASDAQ
O31.32H32.39L31.27C32.00+0.74 (+2.37%)Vol1.62M
News